Novo Nordisk shares were up Wednesday following an earnings report that showed continued sales growth of its obesity drug.

Novo Nordisk posted solid quarterly results Wednesday before the market open.The drug maker’s sales came in at 71.3 billion ...

The Danish company’s share price rise of 7 per cent this year lags far behind its rival Eli Lilly’s 36 per cent, as the US company has gradually increased its share of the obesity and diabetes market ...

Novo Nordisk on Wednesday reported better-than-expected quarterly sales of its popular Wegovy weight-loss drug and narrowed ...

Novo Nordisk's net profit in the third quarter rose 21% to 27.3 billion kroner, ahead of the 26.79 billion kroner forecast by analysts in a FactSet poll. Sales rose 21% to 71.31 billion kroner, ...

Novo Nordisk A/S’s sales of blockbuster weight-loss drug Wegovy beat expectations in the third quarter, a potential relief ...

The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.

Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations ...

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.

We recently compiled a list of the 8 Best European Stocks To Buy According to Hedge Funds. In this article, we are going to ...

Medications like Ozempic and Wegovy, which are used to treat type 2 diabetes and boost weight loss, may also help reduce knee ...

Before Wegovy, 190,000 people in the U.S. were claiming GLP-1 ... with 5.1 percent of white patients with obesity on weight loss drugs compared to just 3.7 percent of Hispanic patients with obesity.